Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA. Wong JY, et al. Among authors: raubitschek aa. Clin Cancer Res. 2004 Aug 1;10(15):5014-21. doi: 10.1158/1078-0432.CCR-03-0576. Clin Cancer Res. 2004. PMID: 15297402 Clinical Trial.
Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.
Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, Williams LE, Yazaki P, Colcher D, Frankel P, Wu A, Raubitschek A, Shively J, Wong JYC. Cahan B, et al. Cancer Biother Radiopharm. 2017 Sep;32(7):258-265. doi: 10.1089/cbr.2017.2223. Cancer Biother Radiopharm. 2017. PMID: 28910150 Free PMC article. Clinical Trial.
Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JY, Colcher D, Wu AM, Raubitschek AA. Yazaki PJ, et al. Among authors: raubitschek aa. Protein Eng Des Sel. 2004 May;17(5):481-9. doi: 10.1093/protein/gzh056. Epub 2004 Aug 17. Protein Eng Des Sel. 2004. PMID: 15316127
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM. Kenanova V, et al. Among authors: raubitschek aa. Cancer Res. 2005 Jan 15;65(2):622-31. Cancer Res. 2005. PMID: 15695407 Free PMC article.
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM. Olafsen T, et al. Among authors: raubitschek aa. Cancer Res. 2005 Jul 1;65(13):5907-16. doi: 10.1158/0008-5472.CAN-04-4472. Cancer Res. 2005. PMID: 15994969 Free PMC article.
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA. Wong JY, et al. Among authors: raubitschek aa. Cancer Biother Radiopharm. 2006 Apr;21(2):88-100. doi: 10.1089/cbr.2006.21.88. Cancer Biother Radiopharm. 2006. PMID: 16706629 Clinical Trial.
132 results